Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Novel Technique Reveals Potential Pathways that Control Protein Function

A new method developed by researchers at the Centre for Genomic Regulation (CRG) in Barcelona has revealed the number of potential therapeutic targets on the surfaces of human proteins is much greater than previously thought. The findings of a new study in the

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

A new method developed by researchers at the Centre for Genomic Regulation (CRG) in Barcelona has revealed the number of potential therapeutic targets on the surfaces of human proteins is much greater than previously thought.

The findings of a new study in the journal Nature, in a paper titled, “Mapping the energetic and allosteric landscapes of protein-binding domains.”

“Allosteric communication between distant sites in proteins is central to biological regulation but still poorly characterized, limiting understanding, engineering, and drug development,” the researchers wrote. “An important reason for this is the lack of methods to comprehensively quantify allostery in diverse proteins. Here we address this shortcoming and present a method that uses deep mutational scanning to globally map allostery.”

The method, in which tens of thousands of experiments are performed at the same time, has been used to chart the first ever map of these elusive targets, also known as allosteric sites, in two of the most common human proteins, revealing they are abundant and identifiable.

“Not only are these potential therapeutic sites abundant, there is evidence they can be manipulated in many different ways. Rather than simply switching them on or off, we could modulate their activity like a thermostat. From an engineering perspective, that’s striking gold because it gives us plenty of space to design ‘smart drugs’ that target the bad and spare the good,” explained André Faure, PhD, postdoctoral researcher at the CRG and co-first author of the paper.

The technique is called double deep PCA (ddPCA), which the researchers describe as a “brute force experiment.” ICREA research professor Ben Lehner, PhD, coordinator of the systems biology program at the CRG and author of the study explained: “We purposefully break things in thousands of different ways to build a complete picture of how something works. It’s like suspecting a faulty spark plug, but instead of only checking that, the mechanic dismantles the entire car and checks it piece by piece. By testing ten thousand things in one go we identify all the pieces that really matter.”

The method works by changing the amino acids that make up a protein, resulting in thousands of different versions of the protein with just one or two differences in the sequence. The effects of the mutations are then tested all at the same time in living cells in the laboratory.

“Each cell is a tiny factory making a different version of the protein. In a single test tube, we have millions of different factories and so we can very rapidly test how well all the different versions of a protein work,” added Lehner.

“While some tools can predict a protein’s structure by reading its sequence, our method goes one step further by telling us how a protein works. This is part of a bigger vision to make biology as engineerable as airplanes, bridges, or computers. We have faced the same challenges for over 70 years, but it turns out they are more tractable than we previously thought. If we succeed it will open a new field with unprecedented possibilities,” concluded Lehner.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →